Wells Fargo & Company Gemini Therapeutics, Inc. Transaction History

Wells Fargo & Company

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.31 - $2.01 $2 - $4	-2 Reduced 1.35%	146 $0
Q2 2022 Aug 12, 2022	SELL	$1.22 - $1.73 $58,017 - $82,270	-47,555 Reduced 99.69%	148 $0
Q1 2022 May 16, 2022	BUY	$1.29 - $3.08 $35,280 - $84,234	27,349 Added 134.37%	47,703 $66,000
Q4 2021 Feb 14, 2022	BUY	$2.39 - $4.0 $7,050 - $11,800	2,950 Added 16.95%	20,354 $59,000
Q3 2021 Nov 15, 2021	SELL	$3.3 - $6.32 $26,611 - $50,964	-8,064 Reduced 31.66%	17,404 $70,000
Q2 2021 Aug 16, 2021	BUY	$6.32 - $14.02 $159,712 - $354,299	25,271 Added 12827.92%	25,468 $165,000
Q1 2021 May 13, 2021	BUY	$11.32 - $18.0 $2,230 - $3,546	197 New	197 $3,000

2.44M

Ticker GMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,244,500
Market Cap $1.05B
Description
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 ...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.